Food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose

A pharmaceutical composition and technology of lactic acid bacteria, applied in the direction of medical preparations containing active ingredients, lactobacillus, dairy products, etc., can solve problems such as differences in the ability to control fasting blood sugar

Pending Publication Date: 2020-12-15
锦乔生物科技有限公司
View PDF12 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The results showed that the hypoglycemic ability of the NCDC 17 strain was significantly better than that of the GG strain, and the ability of the two strains to control fasting blood sugar was also significantly different
In addition, only the NCDC 17 strain has the effect of controlling blood insulin, glycosylated hemoglobin, triglyceride, and cholesterol, while the GG strain has no such effect, indicating that although it is the same lactobacillus, it is effective in improving the symptoms of diabetes strain-specific

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose
  • Food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose
  • Food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Embodiment 1: Morphological and general properties of the lactic acid bacteria strain of the present invention

[0055] The taxonomic characteristics of the strains will be confirmed according to the results of 16S rDNA sequence analysis and API bacterial identification system analysis. The morphological and general characteristics of the above strains are listed in Table 2:

[0056] Morphological and general property characteristics of the lactic acid bacteria strain of the present invention

[0057]

Embodiment 2

[0058] Example 2: Screening of lactic acid bacteria strains with monosaccharide metabolism ability by in vitro tests

[0059] In the present embodiment, the lactic acid bacteria used include Lactobacillus salivarius (Lactobacillus salivarius) AP-32 strain, gL-28 strain and gL-65 strain, Lactobacillus johnsonii (Lactobacillus johnsonii) MH-68 strain and gL-84 strain, Lactobacillus reuteri GL-104 strain, gL-21 strain and gL-22 strain, Lactobacillus acidophilus TYCA06 strain, TYCA01 strain and gL-97 strain, Lactobacillus paracasei ) GL-106 strain and GL-156 strain, Lactobacillus rhamnosus (Lactobacillus rhamnosus) CT-53 strain, GL-165 strain, F-1 strain and bv-77 strain, plant Lactobacillus (Lactobacillus plantarum) LPL28 strain and gL-305 strain, Lactobacillus casei CS-773 strain and gL-10 strain, Lactobacillus helveticus RE-78 strain and gL-72 strain, Enterococcus faecium YM-66 strain and YM-73 strain, Bifidobacterium animalis subsp.lactis BB-115 strain and CP-9 strain, Bifido...

Embodiment 3

[0063] Example 3: Screening of lactic acid bacteria strains capable of metabolizing mixed monosaccharides by in vitro tests

[0064] In this example, each of the above strains was inoculated with 1×10 8 The CFU is in the culture medium, wherein the culture medium is MFG culture medium (containing glucose 20mg / ml, fructose 20mg / ml, and galactose 20mg / ml). Then, after culturing in a 37°C incubator for 20 hours, the supernatant was collected, and the reducing sugar concentration was analyzed with DNS reagent (27.4mM 3,5-Dinitrosalicylic acid, 524mM Sodium hydroxide and 879mM Potassium sodium tartrate), and then the mixing of each strain was calculated. Monosaccharide utilization (%).

[0065] Please refer to figure 2 , the results show that Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus johnsonii, and Lactobacillus acidophilus have a better ability to metabolize mixed monosaccharides than other lactic acid bacteria and bifidobacteria in a mixed monosaccharide e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

Description

technical field [0001] The present invention relates to a food composition and a medical composition, in particular to a food composition and a medical composition containing lactic acid bacteria strains for lowering blood sugar. Background technique [0002] Metabolic syndrome has become an increasingly common condition in recent years due to changes in diet and lifestyle, in which high blood sugar can lead to diabetes. Diabetes is a disease caused by long-term metabolic disorders, and may be related to some complications, including cardiovascular disease, stroke, blindness, kidney failure or Alzheimer's disease. Therefore, the prevention and treatment of hyperglycemia deserves attention. [0003] Traditionally used to treat hyperglycemia symptoms is the use of oral hypoglycemic drugs, oral hypoglycemic drugs can be divided into six types, including: 1) sulfonylureas, such as: Amaryl (Maer pancreas), Glibenclamide (sugar level), Minidiab ( Eliminate diabetes), Diamicron (D...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A23L33/135A61K35/747A61P3/10
CPCA23L33/135A61K35/747A61P3/10A23V2002/00A23V2400/151A23V2400/181A23V2400/173A23V2400/113A23V2200/30A23C19/062A23C9/1234A61K9/0053C12R2001/23C12R2001/225C12N1/205A23V2200/3204A23V2200/328A23C9/1232A23C19/0323
Inventor 谢佩珊郭仲伟蔡宜钧何协勋郭易纬
Owner 锦乔生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap